Skip to Content

WCLC: Tam-Peli in Relapsed SCLC

The phase III TAISHAN-302 study compared Tam-Peli with topotecan in patients with relapsed small cell lung cancer. In this MEDtalk, Dr. Li Zhang, Professor and Deputy Director, Sun Yat-sen University Cancer Center, China, presents results showing significant improvements in overall survival, progression-free survival and response rate with Tam-Peli. Dr. Zhang also discusses intracranial activity and the safety profile observed in the study.

Zhang Li

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top